Diaryl ethers with carboxymethoxyphenacyl motif as potent HIV-1 reverse transcriptase inhibitors with improved solubility

References

• Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112–6.
   PubMed Web of Science ®Google Scholar
• De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998;38:153–79.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003;362:22–9.
   PubMed Web of Science ®Google Scholar
• de Béthune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res 2010;85:75–90.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Eron JJ, Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. J Am Med Assoc 2008;300:555–70.
   PubMed Web of Science ®Google Scholar
• Kakuda TN. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 2000;22:685–708.
   PubMed Web of Science ®Google Scholar
• Martins S, Ramos MJ, Fernandes PA. The current status of the NNRTI family of antiretrovirals used in the HAART regime against HIV infection. Curr Med Chem 2008;15:1083–95.
   PubMed Web of Science ®Google Scholar
• Achuthan V, Keith BJ, Connolly BA, DeStefano JJ. Human immunodeficiency virus reverse transcriptase displays dramatically higher fidelity under physiological magnesium conditions in vitro. J Virol 2014;88:8514–27.
   PubMed Web of Science ®Google Scholar
• Cuevas JM, Geller R, Garijo R, et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251.
   PubMed Web of Science ®Google Scholar
• Roberts JD, Bebenek K, Kunkel TA. The accuracy of reverse transcriptase from HIV-1. Science 1988;25:1171–3.
   Web of Science ®Google Scholar
• Brenner B, Turner D, Oliveira M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. Aids 2003;17:F1–5.
   PubMed Web of Science ®Google Scholar
• Delaugerre C, Rohban R, Simon A, et al. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65:445–8.
   PubMed Web of Science ®Google Scholar
• Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int J Biochem Cell Biol 2004;36:1735–51.
   PubMed Web of Science ®Google Scholar
• Ghosn J, Chaix ML, Delaugerre C. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009;11:165–73.
   PubMed Web of Science ®Google Scholar
• Janssen PAJ, Lewi PJ, Arnold E, et al. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]-amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J Med Chem 2005;48:1901–9.
   PubMed Web of Science ®Google Scholar
• Rajput L, Sanphui P, Desiraju GR. New solid forms of the anti-HIV Drug etravirine: salts, cocrystals, and solubility. Cryst Growth Des 2013;13:3681–90.
   Web of Science ®Google Scholar
• Li X, Zhang L, Tian Y, et al. Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2011–2014). Expert Opin Ther Pat 2014;24:1199–227.
   PubMed Web of Science ®Google Scholar
• Zhan P, Chen X, Li D, et al. HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. Med Res Rev 2013;33:E1–E72.
   PubMed Web of Science ®Google Scholar
• Zhan P, Pannecouque C, De Clercq E, Liu X. Anti-HIV drug discovery and development: current innovations and future trends. J Med Chem 2016;59:2849–78.
   PubMed Web of Science ®Google Scholar
• Das K, Lewi PJ, Hughes SH, Arnold E. Crystallography and the design of anti-AIDS drugs: conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. Prog Biophys Mol Biol 2005;88:209–31.
   PubMed Web of Science ®Google Scholar
• Das K, Clark AD, Jr, Lewi PJ, et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47:2550–60.
   PubMed Web of Science ®Google Scholar
• Bollini M, Domaoal RA, Thakur VV, et al. Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. J Med Chem 2011;54:8582–91.
   PubMed Web of Science ®Google Scholar
• Côté B, Burch JD, Asante-Appiah E, et al. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses. Bioorg Med Chem Lett 2014;24:917–22.
   PubMed Web of Science ®Google Scholar
• National Library of Medicine, National Institutes of Health, USA. https://clinicaltrials.gov/ct2/show/NCT02275780 [last accessed 10 August 2016].
   Google Scholar
• Girardet J-L, Koh Y-H, De La Rosa M, et al. Abstr 47th Intersci Conf Antimicrob Agents Chemother 2007; abstr H-1040.
   Google Scholar
• Hawley M, Morozowich W. Modifying the diffusion layer of soluble salts of poorly soluble basic drugs to improve dissolution performance. Mol Pharm 2010;7:1441–9.
   PubMed Web of Science ®Google Scholar
• Ferris RG, Hazen RJ, Roberts GB, et al. Antiviral activity of GW678248, a novel benzophenone nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother 2005;49:4046–51.
   PubMed Web of Science ®Google Scholar
• Schaller L, Burnette T, Cowan J, et al. Abstr 43rd Intersci Conf Antimicrob Agents Chemother 2003; abstr H-872.
   Google Scholar
• Bollini M, Cisneros JA, Spasov KA, et al. Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility. Bioorg Med Chem Lett 2013;23:5213–6.
   PubMed Web of Science ®Google Scholar
• Bollini M, Frey KM, Cisneros JA, et al. Extension into the entrance channel of HIV-1 reverse transcriptase - Crystallography and enhanced solubility. Bioorg Med Chem Lett 2013;23:5209–12.
   PubMed Web of Science ®Google Scholar
• Sun LQ, Zhu L, Qian K, et al. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. J Med Chem 2012;55:7219–29.
   PubMed Web of Science ®Google Scholar
• Frey KM, Puleo DE, Spasov KA, et al. Structure-based evaluation of non-nucleoside inhibitors with improved potency and solubility that target HIV reverse transcriptase variants. J Med Chem 2015;58:2737–45.
   PubMed Web of Science ®Google Scholar
• Chong P, Sebahar P, Youngman M, et al. Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem 2012;55:10601–9.
   PubMed Web of Science ®Google Scholar
• Tucker TJ, Saggar S, Sisko JT, et al. The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations. Bioorg Med Chem Lett 2008;18:2959–66.
   PubMed Web of Science ®Google Scholar
• Tucker TJ, Sisko JT, Tynebor RM, et al. Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J Med Chem 2008;51:6503–11.
   PubMed Web of Science ®Google Scholar
• Moyle G, Boffito M, Stoehr A, et al. Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects. Antimicrob Agents Chemother 2010;54:3170–8.
   PubMedGoogle Scholar
• Chan DMT, Monaco KL, Wang R-P, Winters MP. New N- and O-arylations with phenylboronic acids and cupric acetate. Tetrahedron Lett 1998;39:2933–6.
   Web of Science ®Google Scholar
• Izumisawa Y, Togo H. Preparation of α-bromoketones and thiazoles from ketones with NBS and thioamides in ionic liquids. Green Sust Chem 2011;1:54–62.
   Google Scholar
• Berman H, Westbrook J, Feng Z, et al. The Protein Data Bank. Nucleic Acids Res 2000;28:235–42.
   PubMed Web of Science ®Google Scholar
• Schrödinger Suite 2016-3 Protein Preparation Wizard; Epik version 3.3, New York, NY: Schrödinger, LLC; 2016. Impact version 6.8, New York, NY: Schrödinger, LLC; 2016. Prime version 4.1, New York, NY: Schrödinger, LLC; 2016.
   Google Scholar
• Frączek T, Siwek A, Paneth P. Assessing molecular docking tools for relative biological activity prediction: a case study of triazole HIV-1 NNRTIs. J Chem Inf Model 2013;53:3326–42.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Banks JL, Murphy RB, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004;47:1739–49.
   PubMed Web of Science ®Google Scholar
• Friesner RA, Murphy RB, Repasky MP, et al. Extra precision Glide: docking and scoring incorporating a model of hydrophobic enclosure for protein ligand complexes. J Med Chem 2006;49:6177–96.
   PubMed Web of Science ®Google Scholar
• Halgren TA, Murphy RB, Friesner RA, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 2004;47:1750–9.
   PubMed Web of Science ®Google Scholar
• Glide, version 5.8. New York, NY: Schrödinger, LLC; 2012.
   Google Scholar
• Höhne K, Businger R, van Nuffel A, et al. Virion encapsidated HIV-1 Vpr induces NFAT to prime non-activated T cells for productive infection. Open Biol 2016;6:160046.
   PubMed Web of Science ®Google Scholar
• Landi A, Vermeire J, Iannucci V, et al. Genome-wide shRNA screening identifies host factors involved in early endocytic events for HIV-1-induced CD4 down-regulation. Retrovirol 2014;11:118.
   PubMed Web of Science ®Google Scholar
• Vermeire J, Roesch F, Sauter D, et al. HIV triggers a cGAS-dependent, Vpu- and Vpr-regulated type I interferon response in CD4(+) T Cells. Cell Rep 2016;17:413–24.
   PubMed Web of Science ®Google Scholar
• Morelock MM, Choi LL, Bell GL, Wright JL. Estimation and correlation of drug water solubility with pharmacological parameters required for biological activity. J Pharm Sci 1994;83:948–52.
   PubMed Web of Science ®Google Scholar
• Grob PM, Wu JC, Cohen KA, et al. Nonnucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug. AIDS Res Hum Retroviruses 1992;8:145–52.
   PubMed Web of Science ®Google Scholar